SCHEMBL78898

SCHEMBL78898

C1CC(C2CC2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22374 1.00
SCHEMBL22129611 1.00
SCHEMBL2994808 0.95 ALDH1A1 (0.80)
SCHEMBL597999 0.94
SCHEMBL1004477 0.94
SCHEMBL18075 0.94
SCHEMBL20193393 0.89 ALDH1A1 (0.89)
SCHEMBL3767440 0.89 ALDH1A1 (0.89)
SCHEMBL21841873 0.89 ALDH1A1 (0.89)
SCHEMBL18897676 0.89 ALDH1A1 (0.89)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1920 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384520-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 EP claimed
US-20240174679-A1 HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2024-05-30 US claimed
US-20240109836-A1 NON-HALLUCINOGENIC ARIADNE ANALOGS FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-04-04 US claimed
WO-2024073601-A2 ARIADNE AND ANALOGS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROMUSCLAR DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-04-04 WO claimed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 WO claimed
EP-4308115-A1 HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Merck Sharp & Dohme LLC (US) 2024-01-24 EP claimed
WO-2024012570-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF 西藏海思科制药有限公司 2024-01-18 WO claimed
WO-2023232133-A1 COMPOUND FOR INHIBITING OR DEGRADING BCL6 AND USE THEREOF IN PHARMACEUTICS 西藏海思科制药有限公司 2023-12-07 WO claimed
CN-116940575-A Thienopyrimidinedione compounds and application thereof 深圳市康哲药业有限公司 2023-10-24 CN claimed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP claimed
EP-1009738-A1 SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-06-21 EP claimed
EP-0960108-A1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA &amp; UPJOHN S.p.A. (IT) 1999-12-01 EP claimed
WO-1999015500-A1 SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-04-01 WO claimed
WO-1998033788-A1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA & UPJOHN S.P.A. (IT) 1998-08-06 WO claimed
WO-1996035680-A1 SULPHONYLAMINO(THIO)CARBONYLTRIAZOLIN(THI)ONES WITH ARYLOXY OR ARYLTHIO SUBSTITUENTS BAYER AKTIENGESELLSCHAFT (DE) 1996-11-14 WO claimed
WO-1995011898-A1 CONDENSED PYRIDINE TYPE MEVALONOLACTONE INTERMEDIATE AND PROCESS FOR ITS PRODUCTION NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1995-05-04 WO claimed
EP-0539976-A1 Ethynyl-alanine-amino-diol compounds for treatment of hypertension G.D. Searle & Co. (US) 1993-05-05 EP claimed
EP-0535548-A1 Inhibitor of atherosclerotic intimal thickening NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1993-04-07 EP claimed
EP-0361341-A2 Therapeutics for aids based on inhibitors of HIV protease MILES INC. (US) 1990-04-04 EP claimed
US-4428937-A OXAPENICILLINS; BETA-LACTAMASE INHIBITORS BEECHAM GROUP LIMITED (GB) 1984-01-31 US claimed